

AUG 01 2005

SCHERING-PLOUGH CORPORATION
LAW DEPARTMENT
2000 GALLOPING HILL ROAD
K-6-1, MAIL STOP 1990
KENILWORTH, NEW JERSEY 07033
(908) 298-4000

FACSIMILE TRANSMITTAL SHEET

TO: Examiner: Evelyn Huang
USPTO FAX NUMBER:
(703) 872-9306

FROM: Palaiyur S. Kalyanaraman PHONE NUMBER:
(908) 298-5068

TOTAL NO. OF PAGES INCLUDING COVER DATE
15 August 1, 2005

CONFIDENTIALITY NOTE: This sheet and/or the document(s) accompanying it contain information belonging to Schering-Plough Corporation and/or its affiliates which is confidential and/or legally privileged. The information is intended only for the use of the individual or entity named above. If you have received this fax in error, please immediately notify us by telephone. If there is a problem with this transmission please call Ashly Armstrong at (908) 298-4025.

NOTES/COMMENTS:


PLEASE HAND DELIVER

In re Application of: Michael P. Dwyer *et al.*
For Patent entitled: "Novel Imidazopyridines as Cyclin Dependent Kinase Inhibitors"
Group Art Unit: 1625
Filed: 09/17/2003
Attorney Docket No.: OC01628K
Serial No.: 10/664,338

Dear Examiner Huang,

Transmitted herewith are:

- > Fax Cover Sheet - 1pg.
- > Response Transmittal - 1pg.
- > Extension of Time Request (2 months) - 1pg. in duplicate
- > Response - 11pgs.


Palaiyur S. Kalyanaraman
Registered Representative
Registration No. 34,634

Express Mail Label No.

PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/664,338	
	Filing Date	09/17/2003	
	First Named Inventor	Michael P. Dwyer	
	Art Unit	1625	
	Examiner Name	Evelyn Huang	
Total Number of Pages in This Submission	15	Attorney Docket Number	OC01628K


ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		

Fax Cover Sheet - 1pg.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Customer No. 24265		
Signature			
Printed name	PALAIYUR S. KALYANARAMAN		
Date	08/01/2005	Reg. No.	34,634

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:			
Signature			
Typed or printed name	PALAIYUR S. KALYANARAMAN	Date	08/01/2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

AUG 01 2005

PATENT: OC01628K

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

5 In re Application of _____X
Michael P. Dwyer *et al.* : Examiner: Evelyn Huang
Appln. No.: 10/664,338 : Group Art Unit: 1625
10 Filed: September 17, 2003 :
For: "Novel Imidazopyridines as Cyclin :
Dependent Kinase Inhibitors" :
15 _____X

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

20 Sir:

RESPONSE TO NOTICE OF NON-COMPLIANT AMENDMENT
AMENDMENT AFTER FINAL REJECTION PER 37 C.F.R § 1.116

25 This communication is in response to the Notice of Non-compliant
Amendment that the Examiner issued on July 15, 2005, in the above-identified
patent application, which followed Applicants' Response filed on June 28, 2005.
Claims 1-19, 29 and 31 are pending in this case. Applicants respectfully request
entry and consideration of this Response to the Non-compliant amendment. Also
30 enclosed is an extension fee for two months. This Response is being faxed to the
Examiner's attention at 703-872-9306.

Amendments to the Claims are reflected in the listing of claims which begins on
page 2 of this paper.

Remarks begin on page 15 of this paper.